Dr. Howard M. Belmont, MD

Dr. Belmont practices at Nyu Langone Orthopedic Hospital-Immediate Care - HOPD in New York, New York.

Dr. Belmont's NPI, 1992779441, was assigned on February 13, 2006. Dr. Belmont graduated from University of Pittsburgh School of Medicine in 1980. Dr. Belmont holds New York license 146362.

Dr. Belmont's primary practice is Nyu Langone Orthopedic Hospital-Immediate Care - HOPD, at 301 E 17th St, New York, NY 10003.

Dr. Belmont's primary practice is Nyu Langone Orthopedic Hospital-Immediate Care - HOPD in New York, New York. Dr. Belmont is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Belmont to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Belmont practices, 4 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Belmont's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Belmont is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Belmont's licenses on file in 2 states: New York and Florida.

Dmand AI lists arthritis, gout, joint arthropathy, joint pain, lupus, muscle pain, fibromyalgia, and limb pain, osteoporosis and purpura and thrombocytopenia among the conditions Dr. Belmont treats.

CMS data shows 429 Medicare services from Dr. Belmont across 5 procedure codes in 2024, for 72 Medicare patients. Medicare paid $27,194 for them.

CMS counts 72 Medicare patients who saw Dr. Belmont in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 26% are also on Medicaid. Their average risk score is 3.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Belmont's median patient age at 71, with 83% women.

In 2024, Dr. Belmont wrote 589 Medicare Part D claims for 69 patients. 83% of them were for generic drugs. CMS names the drug for 378 of them, across 12 drugs with 11 or more claims each, at $593,949 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Belmont for performance year 2024, reported as part of a group. Dr. Belmont accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Belmont as offering telehealth.

Dmand AI links 63 papers to Dr. Belmont, published from 2009 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Lupus Erythematosus, Systemic, Antiphospholipid Syndrome and Lupus Nephritis. Dr. Belmont has published most often in Lupus Sci Med. Dr. Belmont's most frequent co-authors are Peter M. Izmirly, MD, Jill P. Buyon, MD and Doruk Erkan, MD.

Dmand AI links Dr. Belmont to 1 clinical trial. Conditions studied include Osteonecrosis and Necrosis.

CMS Open Payments shows 22 general payments to Dr. Belmont from 2 drug and device companies in 2025. Consulting fees make up the largest share, 61% of the total. Alexion Pharmaceuticals, Inc. paid the most, $16,751.

Dmand AI lists 4 awards for Dr. Belmont, most recently CMS Stage 1 EHR in 2013.

Dr. Belmont graduated from University of Pittsburgh School of Medicine in 1980.

Dr. Belmont is in network with 17 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.